Berkshire’s disclosure of its new position in Teva ($TEVA) set a bottom for the stock. Though revenue is getting crushed by generic competition and Copax sales will dwindle to ~ 0 over the long-term, the company is financially fine and has a plan. $TEVA, Teva Pharmaceutical Industries Limited / H1 Cutting that debt will progress in 2018 as Teva sells down non-core assets. User @ jjjackpot writes: “I have confidence in Kare Schultz, the new turn-around CEO well known for his talent and expertise at turning companies around. In addition, TEVA makes very high-quality drugs that indeed work. They have a huge pipeline that will yield many more useful drugs in the future. Investing in TEVA is not for day traders who watch every quarter that this country is known for. Follow Warren B's advice for long-term investing; in spite of the dividend drop, I'm confident that they will return to paying it in the future. Hang in there and you'll be rewarded.” - Teva has at least three major products set for replacing lost Copax sales. Debt is falling and cash flow will turn stronger. Related: Valeant ($VRX) fell below my $19 - $20 PT but also benefits as markets warm up to generic suppliers like Teva, Mylan $MYL. Allergan $AGN will bounce back as markets recognize its generic unit sale will strengthen the company’s potential revenue growth. VRX: $BHC, Bausch Health Companies Inc. / H1 AGN: $AGN, Allergan plc / H1 TEVA Bottomed at $20. Agree or disagree? Login now to vote. Join the group of Value Stocks. With 800 members strong. Post a comment and create a conversation.